| lisdexamfetamine / Generic mfg. |
NCT00500071: Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD |
|
|
| Completed | 4 | 318 | US | Vyvanse (lisdexamfetamine dimesylate) | Shire | Attention Deficit Hyperactivity Disorder (ADHD) | 01/08 | 01/08 | | |
| Completed | 4 | 42 | US | Vyvanse, lisdexamfetamine dimesylate | Kimberley Lakes, Shire | Attention Deficit/Hyperactivity Disorder | 09/09 | 09/09 | | |
NCT00877487: Safety and Efficacy of Vyvanse in Adults With Attention-Deficit/Hyperactivity Disorder |
|
|
| Completed | 4 | 123 | US | SPD489 (Lisdexamfetamine dimesylate), Vyvanse, Placebo | Shire | Attention-Deficit/Hyperactivity Disorder | 07/10 | 07/10 | | |
NCT01101022: Safety and Efficacy of SPD489 on Executive Function Behaviors in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) |
|
|
| Completed | 4 | 161 | US | SPD489, Vyvanse, Placebo | Shire | ADHD Specifically With Executive Function Impairment | 11/10 | 11/10 | | |
NCT01070394: Effectiveness and Duration of Effect of Open Treatment in Attention Deficit Hyperactivity Disorder (ADHD) Patients Treated With Lisdexamfetamine Dimesylate(Vyvanse) |
|
|
| Completed | 4 | 40 | US | LDX Treatment, Vyvanse | NYU Langone Health, Shire | Attention Deficit Hyperactivity Disorder | 07/12 | 07/12 | | |
NCT01552915: Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder |
|
|
| Completed | 4 | 464 | US | Lisdexamfetamine dimesylate, LDX, Vyvanse, SPD489, Methylphenidate Hydrochloride, OROS-MPH, Concerta, Placebo | Shire | Attention-deficit/Hyperactivity Disorder | 01/14 | 01/14 | | |
NCT01324024: Attention & Memory Impairments in Menopausal Women |
|
|
| Completed | 4 | 35 | US | Lisdexamfetamine, Vyvanse®, Placebo | University of Pennsylvania, Shire | Symptomatic Menopause, Cognitive Impairments | 04/14 | 04/14 | | |
| Completed | 4 | 549 | Europe, Canada, US | Lisdexamfetamine dimesylate, SPD489, Vyvanse, LDX, Methylphenidate Hydrochloride, Concerta, OROS-MPH, Placebo | Shire | Attention-deficit/Hyperactivity Disorder | 05/14 | 05/14 | | |
NCT01148979: Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder. |
|
|
| Completed | 4 | 35 | US | Lisdexamfetamine Dimesylate (Vyvanse), Vyvanse, Placebo, Sugar pill | Mclean Hospital, Shire | Major Depressive Disorder | 09/14 | 10/14 | | |
NCT01328756 / 2010-020951-30: Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) |
|
|
| Completed | 4 | 314 | Europe | Lisdexamfetamine dimesylate, Vyvanse, SPD489, LDX | Shire | Attention Deficit Hyperactivity Disorder (ADHD) | 09/14 | 09/14 | | |
| Terminated | 4 | 6 | US | Lisdexamfetamine, Vyvanse | University of California, Davis, Shire | Attention Deficit Hyperactivity Disorder | 06/15 | 06/15 | | |
TMF, NCT01816074: Sequencing Treatments for Mothers With ADHD and Their At - Risk Children |
|
|
| Completed | 4 | 53 | US | Vyvanse (lisdexamphetamine), Lisdexamfetamine, Behavior Parent Training, BPT | Seattle Children's Hospital, Shire | Attention Deficit Hyperactivity Disorder | 10/16 | 05/17 | | |
NCT01863459: Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder Comorbidity |
|
|
| Completed | 4 | 42 | Canada | Lisdexamfetamine Dimesylate, Vyvanse, placebo | Centre for Anxiety, Attention Deficit and Trauma, Ontario, Canada, Shire | Adult Attention Deficit Hyperactivity Disorder (ADHD) With Co-occuring Anxiety and Depressive Disorders | 03/17 | 03/17 | | |
TBIC, NCT02712996: Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children |
|
|
| Completed | 4 | 20 | US | Lisdexamfetamine, Vyvanse, Placebo | Vanderbilt University, Shire | Traumatic Brain Injury, Attention Deficit Disorder | 07/19 | 07/19 | | |
| Completed | 4 | 257 | Canada | Methylphenidate Hydrochloride, FOQUEST, ADHANSIA XR, Lisdexamfetamine Dimesylate, VYVANSE | Purdue Pharma, Canada | Attention Deficit-Hyperactivity Disorder | 07/21 | 07/21 | | |
NCT03337646: Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism |
|
|
| Completed | 4 | 48 | Canada | Lisdexamfetamine Dimesylate, Vyvanse | JPM van Stralen Medicine Professional, Shire | Attention Deficit Hyperactivity Disorder, Autism Spectrum Disorder | 03/23 | 03/23 | | |
